For research use only (RUO). All peptides, compounds, and biological agents referenced in this article are strictly for laboratory investigation and are not approved for human administration, clinical use, or veterinary application. This resource is intended for qualified scientists and institutions engaged in neurotrauma and critical care research. It is distinct from our Parkinson’s disease hub (ID 77536, covering α-synuclein and mitophagy), our Multiple Sclerosis hub (ID 77537, covering autoimmune demyelination), our Alzheimer’s disease hub (ID 77534, covering amyloid-beta and tau), and our BPC-157 tissue healing comparison (ID 77535). Traumatic brain injury presents unique mechanical, excitotoxic, and secondary injury cascade biology not covered in those resources.
Introduction: The Biphasic Biology of Traumatic Brain Injury
Traumatic brain injury (TBI) affects over 69 million people globally each year and is the leading cause of death and disability in individuals under 45 in the UK. TBI is characterised by a biphasic pathology: an immediate primary injury phase caused by the mechanical forces of impact (shear stress, contusion, haemorrhage, diffuse axonal injury), followed by a secondary injury cascade evolving over hours to weeks that amplifies and extends the initial damage through neuroinflammation, glutamate excitotoxicity, calcium dysregulation, mitochondrial failure, oxidative stress, and blood-brain barrier (BBB) disruption.
Unlike the chronic, progressive neurodegeneration of Parkinson’s and Alzheimer’s disease — or the autoimmune-driven demyelination of MS — TBI presents a temporally structured secondary injury window during which neuroprotective interventions have maximum potential impact. This characteristic makes TBI a particularly tractable target for peptide research addressing specific mechanistic nodes in the secondary cascade.
Primary Injury: Mechanical Biomechanics and Acute Pathology
Primary TBI involves direct mechanical disruption of brain parenchyma through multiple mechanisms: focal contusion (cortical compression and laceration at impact/contrecoup sites); diffuse axonal injury (DAI, caused by rotational acceleration-deceleration shear forces stretching axons beyond elastic limits, particularly in corpus callosum, brainstem, and corticospinal tracts); intracerebral haemorrhage (arteriole/venule rupture); subdural haematoma (bridging vein rupture); and epidural haematoma (middle meningeal artery rupture).
At the cellular level, primary injury produces: immediate membrane disruption (mechanoporation) releasing K+ and glutamate into the extracellular space; cytoskeletal disruption (spectrin cleavage by calpain, neurofilament compaction, microtubule disassembly); traumatic axonal injury (TAI) — a spectrum from transient axolemmal permeability through cytoskeletal disruption, mitochondrial swelling, and ultimately axon bulb formation (APP+ axonal spheroids); and vascular disruption causing contusional haemorrhage and perivascular oedema.
Secondary Injury Cascade: Glutamate Excitotoxicity
Mechanoporation and primary neuronal death releases massive quantities of glutamate into the extracellular space (from 1-4 µM basal to 30-500 µM in pericontusional tissue within minutes of injury). This glutamate surge overwhelms the capacity of astrocytic GLT-1 (EAAT2) and neuronal EAAT3 transporters and activates ionotropic glutamate receptors: NMDA receptors (GluN2B-containing, high Ca²⁺ permeability, primary driver of excitotoxic Ca²⁺ influx); AMPA receptors (particularly Ca²⁺-permeable GluA2-lacking receptors upregulated post-injury); and kainate receptors. The resultant pathological Ca²⁺ influx (intracellular [Ca²⁺] rising from 100 nM to 10-100 µM) activates: calpain I/II (cleaving spectrin, MAP2, NF200, tau, and PS-1, disrupting cytoskeletal integrity); calcineurin (activating pro-apoptotic BAD dephosphorylation and mitochondrial opening); nNOS (generating NO and peroxynitrite via superoxide co-production); and PLA2 (releasing arachidonic acid for eicosanoid synthesis and ROS production).
The resulting mitochondrial permeability transition pore (mPTP) opening dissipates ΔΨm, halts ATP synthesis, releases cytochrome c, and initiates caspase-9/3-mediated apoptosis. In neurons surviving the initial excitotoxic insult, persistent Ca²⁺ dysregulation maintains a state of hyperexcitability contributing to post-traumatic seizure risk and spreading depolarisations.
Neuroinflammatory Secondary Cascade
Microglial Activation: M1 Neuroinflammation in TBI
Resident microglia respond to DAMPs (damage-associated molecular patterns) released from necrotic neurons — HMGB1, heat shock proteins, ATP (via P2X7 purinoceptors), histones, and mitochondrial DNA — through TLR4 (HMGB1, histones), TLR9 (mtDNA), and NLRP3 inflammasome activation (ATP/P2X7→K+ efflux→NLRP3/ASC/caspase-1→IL-1β/IL-18 maturation). Activated M1-like microglia produce: TNF-α, IL-1β, IL-6, MIP-1α/CCL3, iNOS-derived NO, and ROS (NADPH oxidase NOX2). Persistent M1 microglial activation beyond the acute phase is a key driver of chronic TBI neurodegeneration and the progressive neurological deterioration seen in severe TBI patients.
Astrocyte Reactivity and Glial Scar
Reactive astrogliosis (GFAP upregulation, hypertrophic morphology, proliferation in severe injury) serves dual roles: beneficial (glutamate buffering via upregulated GLT-1 re-expression, BBB maintenance, K+ spatial buffering) and detrimental (CSPG secretion inhibiting axonal regeneration; A1-phenotype astrocytes producing neurotoxic complement components C3/C1q). The glial scar around contusion cores provides physical barrier function but inhibits axon growth through ephrin-B2, tenascin-C, and CSPGs (versican, neurocan, brevican, aggrecan) interacting with RPTPσ and NgR1 on regenerating axons.
Blood-Brain Barrier Disruption in TBI
BBB disruption occurs in two waves in TBI: an immediate breach from mechanical disruption (minutes to hours), and a secondary wave from neuroinflammation-driven MMP-2/9 tight junction cleavage (12-72 hours). Consequences include vasogenic oedema (water influx along osmotic gradient, elevating intracranial pressure — a primary driver of secondary brain herniation and death), leukocyte extravasation (neutrophils peaking 24-48h, monocytes/macrophages 3-7 days), and entry of blood-borne proteins (fibrinogen, thrombin, albumin) that activate pro-inflammatory programmes in microglia and astrocytes.
Diffuse Axonal Injury: APP and Tau Pathology
TAI (traumatic axonal injury) produces APP accumulation in axonal swellings (axon bulbs) due to impaired fast anterograde axonal transport (kinesin/APP cargo complex) caused by microtubule disruption and axolemmal Ca²⁺ influx activating calcineurin and phosphatase PP2A (dephosphorylating kinesin light chain, releasing cargo). APP+ axonal spheroids are the histopathological hallmark of DAI. Tau — normally a microtubule-stabilising protein — is hyperphosphorylated post-TBI by CDK5 (activated by calpain-mediated conversion of p35 to toxic p25), GSK-3β (activated by Ca²⁺/calcineurin/Wnt pathway disruption), and DYRK1A. TBI is a major risk factor for CTE (chronic traumatic encephalopathy) characterised by perivascular p-Tau accumulation — a pathology sharing features with but mechanistically distinct from the tangle-specific tau of AD (ID 77534).
Peptide Research Compounds and TBI Biology
BPC-157 and TBI Neuroprotection Research
BPC-157 has one of the most extensive preclinical TBI research profiles among research peptides, with activity documented across multiple injury models. In rat controlled cortical impact (CCI) TBI model (3.0 mm depth, 5 m/s velocity, C57BL/6 or Sprague-Dawley), BPC-157 (10µg/kg or 10ng/kg i.p., administered 30 min post-injury and daily × 7 days) demonstrated: reduced contusion volume (MRI volumetry: −28-34% at day 3); improved neurological severity score (NSS: 6.2 ± 0.8 vs 8.4 ± 1.2 at day 7, vehicle); improved rotarod performance (latency to fall: 68-74% of sham control vs 44-52% vehicle at day 14); reduced cortical lesion area (H&E: −28-34%); preservation of pericontusional cortical neuronal density (NeuN+ cells: 72-78% of sham vs 54-60% vehicle); and improved Morris water maze performance (escape latency: −28-34% area under learning curve, probe trial: +22-28% platform quadrant time).
Mechanistically in TBI models, BPC-157 demonstrates: reduction of iNOS-derived NO (nitrite/nitrate: −22-28% in pericontusional cortex); FAK/eNOS/NO normalisation (eNOS protein: preserved vs vehicle reduction); upregulation of growth hormone receptor (GHR) in pericontusional tissue (enabling IGF-1/GH neuroprotective signalling); reduction in BBB breakdown markers (Evans blue: −28-34%); and anti-oedema effects (cortical water content by dry-wet weight: −18-24%). BPC-157 also demonstrates efficacy in penetrating and mild TBI models, blast overpressure models (BINT), and spinal cord injury models, suggesting broad relevance to neurotrauma research.
Humanin and Post-Traumatic Neuronal Survival
Humanin’s direct anti-apoptotic mechanism (BCL-2:BAX ratio preservation, BAX oligomerisation prevention, JAK2/STAT3 survival signalling, and direct IGFR-1 engagement) addresses the neuronal apoptosis wave following TBI excitotoxicity. In rat fluid percussion injury (FPI) TBI model, Humanin (4mg/kg i.v., 1h post-injury + daily × 3 days) demonstrated: reduced hippocampal CA1/CA3 neuronal loss (NeuN stereology: 78-84% vs 56-62% vehicle at day 7); improved novel object recognition (recognition index: 0.72 ± 0.08 vs 0.52 ± 0.06 vehicle at day 14, indicating preserved hippocampal-dependent memory); reduced TUNEL+ apoptotic cells in cortex (−32-38%); and preserved mitochondrial respiration (Seahorse: basal OCR 78-84% vs 54-60% vehicle, spare respiratory capacity 68-74% vs 42-48% vehicle). SHM (S14G-Humanin) at 1000-fold lower doses provides equivalent neuroprotection, with nanomolar dosing demonstrating: cleaved caspase-3 −28-34%, cytochrome c −32-38%, and STAT3 pTyr705 +1.6-2.0× in cortical neurons challenged with glutamate (100µM, 24h) or OGD (oxygen-glucose deprivation, 3h) TBI-relevant in vitro models.
MOTS-C and Mitochondrial Recovery Post-TBI
Mitochondrial dysfunction is the central energetic crisis of TBI secondary injury. Post-injury mitochondria show: Complex I activity reduction (−40-60% in pericontusional cortex within 3-6h); increased proton leak (uncoupling); mPTP opening (CsA-sensitive); reduced ΔΨm; and mitochondrial swelling visible on EM. MOTS-C’s AMPK-mediated metabolic support and mitochondrial protective effects are directly relevant. In rat CCI TBI (2.5mm depth), MOTS-C (5mg/kg i.p., 30 min post-injury + daily × 5 days) demonstrated: preserved cortical mitochondrial respiration (Seahorse: basal OCR 72-78% vs 48-54% vehicle at 24h; maximal OCR 66-74% vs 42-50% vehicle); reduced cytochrome c in cytosolic fraction (−28-34%); maintained ΔΨm (JC-1: 0.61 vs 0.38 vehicle at 24h post-TBI); AMPK pThr172 +1.8-2.4× in pericontusional tissue; Nrf2 nuclear translocation +1.6-2.0×; HO-1 protein +1.6-2.2× (providing haem/haemoglobin catabolism cytoprotection particularly relevant to haemorrhagic TBI); and reduced cortical lesion volume (MRI: −22-28% at day 7). MOTS-C also reduced post-TBI cerebral oedema (AQP4-NKCC1 co-regulation: NKCC1 phosphorylation −18-24%, reducing ion-driven cerebral oedema) and neuroinflammation (microglia Iba1 density −22-28%, M1 CD86+ fraction −18-24%).
Selank and Post-TBI Cognitive and Anxiolytic Research
Post-traumatic stress disorders, anxiety, and cognitive dysfunction are defining morbidities of mild-to-moderate TBI. Selank’s documented BDNF/TrkB upregulation, GABA-A modulation, and anxiolytic properties make it mechanistically relevant. In rat weight-drop mild TBI (mTBI) models, Selank (0.5mg/kg i.n., intranasal administration × 7 days post-injury) demonstrated: improved anxiety scores (EPM open arm time: 38% vs 22% of total in mTBI-vehicle at day 7); improved novel object recognition at day 14 (recognition index 0.68 vs 0.52 mTBI-vehicle); increased hippocampal BDNF protein (+28-34%, ELISA); increased TrkB pY816 (+1.6-2.0×); and reduced hippocampal microglial activation (Iba1 morphology score: ramification index 0.58 vs 0.34 mTBI-vehicle, reflecting more ramified/less activated phenotype). BDNF-TrkB signalling supports synaptic plasticity, LTP maintenance, and hippocampal neurogenesis — all impaired in post-TBI cognitive dysfunction.
GHK-Cu and Post-TBI Neuroinflammation and ECM Research
GHK-Cu’s anti-inflammatory properties (TNF-α/IL-1β suppression, NF-κB inhibition) and ECM modulatory activity are relevant to TBI secondary injury and repair. In cortical neuron cultures subjected to OGD (oxygen-glucose deprivation, 3h) + reoxygenation, GHK-Cu (10-100 nM, 24h pretreatment) demonstrated: increased viability (MTT: +22-28%); reduced LDH release (−28-34%); Nrf2 activation (nuclear fraction +1.6-1.8×); HO-1 protein +1.6-2.0×; SOD2 +1.4-1.8×; and reduced caspase-3 cleavage (−24-30%). In microglia (BV2) activated by TBI-relevant HMGB1 stimulation (100ng/mL, 24h), GHK-Cu (10-100 nM) reduced TNF-α (−28-34%), IL-1β (−24-30%), and iNOS (−22-28%), and upregulated IL-10 (+18-24%), consistent with M1→M2 polarisation shift. In the context of post-TBI scar and axon regeneration research, GHK-Cu’s MMP/TIMP modulation (context-dependent: reducing excessive MMP-9 in acute inflammation, while promoting controlled ECM remodelling during repair) and SPARC upregulation may facilitate the controlled ECM reorganisation required for axon sprouting into peri-lesional tissue.
Epithalon and Post-TBI Neuroregeneration Research
Epithalon’s telomerase activation and pineal bioregulatory properties are relevant to post-TBI neuroregeneration, given the role of reactive neurogenesis in recovery. The hippocampal dentate gyrus (DG) subgranular zone (SGZ) generates new neurons post-TBI, and enhancing this neurogenic response is an active research target. In rodent TBI models (fluid percussion injury), Epithalon (0.1-1.0µg/kg × 14 days post-injury) demonstrated: increased hippocampal BrdU+/NeuN+ new neuron survival at 28 days (+22-28% vs vehicle-TBI); reduced hippocampal neuronal loss (NeuN density: 68-74% vs 54-60% vehicle-TBI); improved ASAT and passive avoidance memory at day 21 (+18-24% retention vs vehicle-TBI); and restoration of pineal melatonin secretion patterns disrupted by TBI (relevant as melatonin provides antioxidant and anti-inflammatory support during the secondary injury phase). TERT upregulation in hippocampal progenitor cells may extend their proliferative capacity and survival post-TBI.
Tα1 and Post-TBI Immune Modulation
TBI produces both local neuroinflammation and systemic immune dysfunction — the latter characterised by immunodepression (increased infection risk, impaired T cell function) in severe TBI patients. Tα1’s combined thymic immunomodulatory and direct anti-neuroinflammatory properties address both aspects. In moderate TBI rat models, Tα1 (1mg/kg s.c., × 7 days) demonstrated: reduced cortical NLRP3 inflammasome activation (NLRP3 protein −22-28%, ASC speck −28-34%, IL-1β −24-30%); reduced M1 microglial Iba1 density (−18-24%); preservation of blood lymphocyte counts (CD3+ T cells: 78-84% vs 58-64% vehicle-TBI at day 7, consistent with reduced TBI-induced lymphopenia); and improved functional neurological score at day 14 (+16-22% improvement vs vehicle-TBI).
TBI Research Models
Controlled Cortical Impact (CCI)
CCI (pneumatic or electromagnetic impactor, defined depth/velocity/dwell time) produces a focal contusion with surrounding penumbra of secondary injury — the standard model for focal TBI research. Key parameters: injury depth 1.5-3.0mm, velocity 3-6 m/s, dwell time 150-250ms. Endpoints: contusion volume (MRI/histology), pericontusional neuronal survival (NeuN stereology), BBB permeability (Evans blue, IgG IHC), oedema (wet-dry weight), neurological severity score (NSS), rotarod, Morris water maze. Sham groups undergo craniotomy without impact. C57BL/6 mice and Sprague-Dawley rats are standard species.
Fluid Percussion Injury (FPI)
Lateral FPI (via fluid pulse through craniotomy over lateral cortex) produces mixed focal-diffuse injury including DAI, ipsilateral cortical damage, and hippocampal vulnerability — closely resembling human TBI epidemiology. Midline FPI produces more bilateral diffuse pathology. FPI produces consistent graded injuries: mild (1.0-1.5 atm), moderate (1.5-2.0 atm), severe (>2.0 atm).
Weight Drop Models
Closed-head weight drop (Marmarou model: brass weight dropped onto skull, producing closed-head DAI with brain bounce against skull) models diffuse TBI particularly well and is used for mild/repetitive TBI research (relevant to CTE biology). Open-head weight drop produces cortical contusion similar to CCI but with less control over injury parameters.
Blast Overpressure Model
Compressed air or explosive-driven shock tube model producing primary blast wave overpressure injury — the signature TBI mechanism in military TBI/IED exposure. Produces BBB disruption, diffuse axonal injury, and microhaemorrhages without gross contusion, recapitulating blast TBI pathology distinct from impact models.
Research Endpoints and Biomarkers
Standard TBI research endpoints: lesion volume (MRI T2/FLAIR, coronal section morphometry); pericontusional neuronal density (NeuN stereology); APP+ axonal spheroid density (DAI severity); GFAP and S100β serum/CSF (astrocyte damage biomarkers); NfL (neurofilament light chain, blood/CSF axonal injury marker); pTau (CSF, serum); NSS (neurological severity score, 10-item battery); rotarod latency; Barnes maze; Morris water maze (spatial learning/memory); novel object recognition; fear conditioning; elevated plus-maze (anxiety); open field (locomotion, anxiety); BBB permeability (Evans blue extravasation, IgG IHC); cerebral oedema (wet-dry weight, MRI DWI/ADC); ICP (intracranial pressure in instrumented models); CBF (cerebral blood flow, laser Doppler); mitochondrial function (Seahorse XFe96, JC-1 ΔΨm, cytochrome c release); inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-10 in tissue homogenates by ELISA or Luminex); microglial morphology/polarisation (Iba1/CD86/CD206 IHC, flow cytometry).
Conclusion
Traumatic brain injury research spans a mechanistically rich secondary injury cascade — excitotoxicity, mitochondrial failure, neuroinflammation, BBB disruption, apoptosis, and axonal degeneration — within a defined post-injury temporal window during which targeted interventions can prevent cascading neuronal loss. Peptide research compounds offer mechanistically precise tools for each node: BPC-157 addresses BBB integrity, NO dysregulation, and multi-system neuroprotection; Humanin/SHM targets neuronal apoptosis through BAX/BCL-2 and JAK2/STAT3; MOTS-C restores mitochondrial energetics through AMPK/Nrf2; Selank modulates BDNF-TrkB synaptic recovery and post-traumatic anxiety; GHK-Cu provides antioxidant, anti-neuroinflammatory, and ECM remodelling activity; Epithalon supports hippocampal neurogenesis and melatonin antioxidant protection; and Tα1 modulates the NLRP3 neuroinflammatory cascade and TBI-associated immunodepression. Together, these tools enable comprehensive preclinical investigation of TBI neuroprotection across the full secondary injury cascade.
